|
| Tuesday, October 14, 2025 |
|
|
云顶新耀EVM14全球临床稳步推进 中美IND"双获批"后美国首例患者成功入组 |
| 云顶新耀宣布，其通用现货型肿瘤治疗性疫苗EVM14注射液的全球多中心I期临床试验在美国临床研究机构NEXT Oncology Virginia成功入组首例患者。 more info >> |
|
| Thursday, October 9, 2025 |
|
|
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology |
| Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator's efficacy in Asian patients. more info >> |
|
|
雲頂新耀艾曲莫德亞洲多中心Ⅲ期臨床ENLIGHT UC研究（ES101002）結果榮登柳葉刀子刊 展示在亞洲患者中的突破性療效與安全性 |
| 雲頂新耀宣布，其治療中重度活動性潰瘍性結腸炎（UC）的創新藥艾曲莫德（VELSIPITY(R), etrasimod）的亞洲多中心Ⅲ期ENLIGHT UC研究（ES101002）成果近日成功發表於國際頂級學術期刊柳葉刀子刊《The Lancet Gastroenterology & Hepatology》（《柳葉刀胃腸病學和肝病學》），標志著新一代高選擇性S1P受體調節劑在亞洲人群中的療效與安全性獲得全球頂級學術期刊認可。 more info >> |
|
|
?????????????????ENLIGHT UC??(ES101002)????????? ?????????????????? |
| ??????,???????????????(UC)????????(VELSIPITY(R), etrasimod)????????ENLIGHT UC??(ES101002)??????????????????????�The Lancet Gastroenterology & Hepatology�(�???????????�),??????????S1P??????????????????????????????? more info >> |
|
| Friday, September 19, 2025 |
|
|
耐賦康(R)被納入《2025 KDIGO IgA腎病和IgA血管炎臨床實踐管理指南》 成為指南唯一推薦的IgA腎病一線對因治療藥物 |
| 雲頂新耀（HKEX 1952.HK）宣布，其創新藥耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）被納入改善全球腎髒病預後組織（KDIGO）發布的《2025 KDIGO IgA腎病和IgA血管炎臨床實踐管理指南》，成為指南唯一推薦的IgA腎病一線對因治療藥物。 more info >> |
|
|
耐赋康(R)被纳入《2025 KDIGO IgA肾病和IgA血管炎临床实践管理指南》 成为指南唯一推荐的IgA肾病一线对因治疗药物 |
| 云顶新耀（HKEX 1952.HK）宣布，其创新药耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）被纳入改善全球肾脏病预后组织（KDIGO）发布的《2025 KDIGO IgA肾病和IgA血管炎临床实践管理指南》，成为指南唯一推荐的IgA肾病一线对因治疗药物。 more info >> |
|
| Monday, September 1, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
|
雲頂新耀發佈2025年中期業績：雙輪驅動戰略顯效 商業化與創新研發協同發力 |
| 雲頂新耀（01952.HK）公佈了截至2025年6月30日的中期業績報告中報顯示。公司實現收入人民幣4.46億元，同比增長48%；運營費用占收入比重大幅減少40.1個百分點，展現了卓越的運營效率。 more info >> |
|
|
云顶新耀发布2025年中期业绩：双轮驱动战略显效 商业化与创新研发协同发力 |
| 云顶新耀（01952.HK）公布了截至2025年6月30日的中期业绩报告中报显示。公司实现收入人民币4.46亿元，同比增长48%；运营费用占收入比重大幅减少40.1个百分点，展现了卓越的运营效率。 more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
|
|
|
